A novel loss-of-function mutation in LACC1 underlies hereditary juvenile arthritis with extended intra-familial phenotypic heterogeneity.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
02 10 2021
Historique:
received: 04 10 2020
accepted: 19 11 2020
pubmed: 26 1 2021
medline: 30 12 2021
entrez: 25 1 2021
Statut: ppublish

Résumé

To investigate phenotypic and molecular characteristics of a consanguineous family with autosomal-recessive, polyarticular, juvenile isiopathic arthriris (JIA) with extra-articular manifestations, including renal amyloidosis and Crohn's disease, associated with a novel homozygous truncating variant in LACC1. Whole exome sequencing (WES) or targeted Sanger verification were performed in 15 participants. LACC1 expression and cytokine array were analysed in patient-derived and CRISPR/Cas9-generated LACC1-knockout macrophages (Mϕ). A homozygous truncating variant (p.Glu348Ter) in LACC1 was identified in three affected and one asymptomatic family member, and predicted harmful by causing premature stop of the LACC1 protein sequences, and by absence from ethnically-matched controls and public variation databases. Expression studies in patient-derived macrophages (Mϕ) showed no endogenous p.Glu348Ter-LACC1 RNA transcription or protein expression, compatible with nonsense-mediated mRNA decay. WES analysis in the asymptomatic homozygous subject for p. Glu348Ter-LACC1 detected an exclusive heterozygous variant (p.Arg928Gln) in complement component C5. Further complement activity analysis suggested a protective role for the p.Arg928Gln-C5 variant as a phenotypic modifier of LACC1-associated disease. Finally, cytokine profile analysis indicated increased levels of pro-inflammatory cytokines in LACC1-disrupted as compared with wild-type Mϕ. Our findings reinforce the role of LACC1 disruption in autosomal-recessive JIA, extend the clinical spectrum and intra-familial heterogeneity of the disease-associated phenotype, indicate a modulatory effect of complement factor C5 on phenotypic severity, and suggest an inhibitory role for wild-type LACC1 on pro-inflammatory pathways.

Identifiants

pubmed: 33493343
pii: 6119389
doi: 10.1093/rheumatology/keab017
doi:

Substances chimiques

Cytokines 0
Intracellular Signaling Peptides and Proteins 0
LACC1 protein, human 0
CRISPR-Associated Protein 9 EC 3.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4888-4898

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Yonatan Butbul Aviel (Y)

Department of Pediatrics and Pediatric Rheumatology Service, Ruth Children's Hospital, Rambam Health Care Campus.
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.

Ayala Ofir (A)

Laboratory of Molecular Medicine, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.

Ofer Ben-Izhak (O)

Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.
Department of Pathology, Rambam Health Care Campus, Haifa.

Euvgeni Vlodavsky (E)

Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.
Department of Pathology, Rambam Health Care Campus, Haifa.

Netanel Karbian (N)

Department of Medicine, Rheumatology Research Center, Hadassah-Hebrew University Medical Center, Jerusalem.

Riva Brik (R)

Department of Pediatrics and Pediatric Rheumatology Service, Ruth Children's Hospital, Rambam Health Care Campus.
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.

Dror Mevorach (D)

Department of Medicine, Rheumatology Research Center, Hadassah-Hebrew University Medical Center, Jerusalem.

Daniella Magen (D)

Laboratory of Molecular Medicine, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology.
Pediatric Nephrology Institute, Ruth Children's Hospital, Rambam Health Care Campus, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH